“We are proud to name Dr. Floyd Seskin as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson

PLEASANTON, Calif. (PRWEB)
May 22, 2020

NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today announced that Floyd Seskin, M.D., Seskin Urology in Aventura, FL, has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Seskin has achieved a high level of training and experience with the UroLift® System and demonstrated a commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic Hyperplasia (BPH), also known as enlarged prostate.

Recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines, the FDA-cleared Prostatic Urethral Lift procedure using the UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to BPH. The UroLift permanent implants, delivered during a transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue.

The UroLift Center of Excellence program is designed to highlight urologists who are committed to educating their patients on BPH and the UroLift System as a treatment option and consistently seek to deliver excellent patient outcomes and experiences.

“We are proud to name Dr. Floyd Seskin as a UroLift Center of Excellence and provider of care for men with enlarged prostate symptoms using the UroLift System treatment,” said Dave Amerson, president of the Teleflex Interventional Urology business unit. “The UroLift System is a safe and effective treatment that allows physicians to treat men in-office under local anesthesia, so they can experience lasting symptom relief within days after receiving treatment.”

Over 40 million men in the United States are affected by BPH, a condition that occurs when the prostate gland that surrounds the male urethra becomes enlarged with advancing age and begins to obstruct the urinary system. Symptoms of BPH often include interrupted sleep and urinary problems and can cause loss of productivity, depression and decreased quality of life.

Medication is often the first-line therapy for enlarged prostate, but relief can be inadequate and temporary. Side effects of medication treatment can include sexual dysfunction, dizziness and headaches, prompting many patients to quit using the drugs. For these patients, the classic alternative is surgery that cuts, heats or removes prostate tissue to open the blocked urethra. While current surgical options can be very effective in relieving symptoms, they can also leave patients with permanent side effects such as urinary incontinence, erectile dysfunction, and retrograde ejaculation.

About the UroLift® System

The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function*1,2. Patients also experienced a significant improvement in quality of life. Over 100,000 men have been treated with the UroLift System in the U.S. Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure using the UroLift System is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in the U.S., Europe, Australia, Canada, Mexico and South Korea. Learn more at http://www.UroLift.com.

About NeoTract | Teleflex Interventional Urology

A wholly owned subsidiary of Teleflex Incorporated, the Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our initial focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving normal sexual function*1,2. Learn more at http://www.NeoTract.com.

About Teleflex Incorporated

Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit http://www.teleflex.com.

Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.

For Teleflex Incorporated: Jake Elguicze, 610.948.2836

Treasurer and Vice President, Investor Relations

Media:

Nicole Osmer, 650.454.0504

nicole@healthandcommerce.com

*No instances of new, sustained erectile or ejaculatory dysfunction 1. Roehrborn, J Urology 2013 LIFT Study

2.McVary, J Sex Med 2016

MAC00968-01 Rev A

Share article on social media or email:

PORTLAND, Ore. (PRWEB)
May 22, 2020

Help.org, a trusted online resource for individuals who struggle with addiction and their loved ones, has announced the Best Rehab Facilities in Portland, Oregon for 2020. The informational guide recognizes the top 25 rehab facilities based on cost, treatment options, location, accompanying services and more.

According to recent studies, drug overdose is the leading cause of death among people under age 50. In Portland, deaths related to opioid abuse increased significantly from 2011 to 2015. Substance abuse among adolescents is also escalating in Portland with 55 percent of high school students reported using alcohol, 38 percent reported using marijuana, 8 percent reported using prescription drugs without a valid prescription, and 2 percent reported using heroin. With the growing need for accessible and high-quality rehab programs, Help.org has developed a unique ranking process to help connect individuals with treatment providers that meet their needs.

The Help.org research team analyzed thousands of facilities across the country and then identified the most cost-effective and highest rated programs in larger cities like Portland. Each facility was evaluated based on rehabilitation services, treatment approaches, cost, special programs for unique demographics and ancillary services. The website also provides information about drug use and side effects as well as educational articles. For a detailed listing of the Best Rehab Facilities in Portland, Oregon please visit https://www.help.org/drug-and-alcohol-rehab-centers-in-portland-or/

2020 Best Rehab Facilities in Portland, Oregon (in alphabetical order)

A Season for Change Counseling and Hypnosis

532 N. Main Avenue Gresham, OR 97030

503-997-7734

Central City Concern Recovery Center

726 W. Burnside Portland, OR 97209

503-944-4410

Community Services Northwest

1601 East 4th Plain Boulevard Building 17, Suite B-222 Vancouver, WA 98661

360-397-8484

Daybreak Youth Services Vancouver Outpatient Counseling

11818 SE Mill Plain Boulevard Suite 213 and 307 Vancouver, WA 98684

360-750-9635

Hilltop Behavioral Health Center

998 Library Court Oregon City, OR 97045

503-655-8401

Native American Rehabilitation Association of the Northwest Residential Treatment Center

17645 NW St. Helens Highway Scappoose, OR 97231

503-621-1069

Stewart Behavioral Health Center

1002 Library Court Oregon City, OR 97045

503-655-8264

Yamhill County Family and Youth Programs Addiction Treatment Services

420 NE 5th Street McMinnville, OR 97128

503-434-7462

ABOUT HELP.ORG

Help.org is an online resource for individuals who struggle with addiction and their loved ones. The website provides the latest research through scientifically proven methods, community recovery resources as well as information about local financial assistance. Help.org’s team of researchers, activists and writers work together with addiction counselors and other professionals to offer useful and accurate resources to help individuals seeking recovery. To learn more, visit https://www.help.org/.

Share article on social media or email:

“Because of AbbVie’s new funding, A Safe Haven will help serve more referrals of more homeless and COVID-19 positive patients from hospitals throughout the Chicagoland area who require isolation and may be homeless or living in a doubled-up situation.”

CHICAGO (PRWEB)
May 21, 2020

A Safe Haven Foundation (ASHF) has been selected as one of 26 nonprofit organizations to receive a donation from the $5 million AbbVie COVID-19 Community Resilience Fund. The fund was created in March to help nonprofits with their immediate response to COVID-19 and support the needs of their frontline homeless workers in service to vulnerable populations in hard-hit communities.

“We are humbled and honored to be named a charitable partner with AbbVie to help fulfill their goals for their program, which includes providing frontline workers with much needed critical personal protective equipment, providing families access to housing, healthcare and behavioral health care, to support vital services for homeless and at-risk populations,” said Neli Vazquez-Rowland, president and co-founder of ASHF, a 501(c)3 not for profit, social enterprise that helps people aspire, transform and sustain their lives as they transition from homelessness to self-sufficiency with pride and purpose. “The much-needed funding will go right to work on the front lines, including protecting our staff, and will help us prevent the spread of the novel coronavirus among our 400 homeless living in our bed facility, and provide services to COVID-19 positive homeless in the co-located and segregated, 100-bed, COVID-19 isolation space.”

ASHF was a first mover in opening up Chicago’s first isolation space on April 11 to serve homeless people who have tested positive for COVID-19 and are asymptomatic or have symptoms but do not require hospitalization. The Center provides homeless individuals with a safe environment to shelter-in-place and also receive the healthcare, behavioral healthcare, nutrition, and support they need.

The Isolation Space was created through a partnership between A Safe Haven Foundation, The City of Chicago Department of Public Health, and Rush University Medical Center (RUMC). Patients in the Isolation Center are seen by RUMC staff, either in-person or by telehealth, and ASHF Haven staff monitors patient progress and offers telebehavioral healthcare services. Thanks to the city and other private funders, the Isolation and Medical Respite Center added an HVAC negative air system in compliance with the strictest aerosol air flow system to avoid cross contamination with the rest of the 400-bed facility at 2750 Roosevelt Rd. in the North Lawndale community. A Safe Haven is an anchor organization and considered the largest single integrated model serving and meeting the needs of the homeless in Chicago.

A Safe Haven is strategically located in the most poverty stricken North Lawndale neighborhood, and adjacent to the Little Village community where residents are disproportionately African American and LatinX. Together they represent the highest numbers of deaths from COVID-19 in Cook County. As the virus emerged, A Safe Haven was a bellwether, calling attention to the susceptibility and vulnerability of the homeless to the virus, their inability to shelter-in-place, and the resulting risk to public health. A Safe Haven has not experienced a COVID-19 outbreak because of its unique semi-private suites and rigorous infection control policies.

“Because of AbbVie’s new funding, A Safe Haven will help serve more referrals of more homeless and COVID-19 positive patients from hospitals throughout the Chicagoland area who require isolation and may be homeless or living in a doubled-up situation,” said Vazquez-Rowland. “Upon discharge from the Isolation Center, we can refer them to an appropriate level of care or provide direct assistance or provide services to address their individual root causes of poverty and homelessness such as substance abuse, education, unemployment or lack of affordable housing.”

About A Safe Haven

A Safe Haven Foundation is a 501(c)3 not for profit, social enterprise that helps people aspire, transform and sustain their lives as they transition from homelessness to self-sufficiency with pride and purpose. For more than 25 years, A Safe Haven has provided the tools for each individual to overcome the root causes of homelessness through a holistic and scalable model which includes substance abuse treatment, education, job training and employment, and phased-housing. A Safe Haven’s visible social and economic impact unites families, stabilizes neighborhoods, and creates vibrant, viable communities. For more information, visit asafehaven.org, or follow them on Facebook, Twitter, Instagram, or Youtube.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at http://www.abbvie.com. Follow @abbvie on Twitter, Facebook, LinkedIn or Instagram.

Share article on social media or email:

Early and appropriate care by a gynecologic oncologist can help increase survival rates in women with ovarian cancer and decrease the number of complications.

MALVERN, Pa. (PRWEB)
May 21, 2020

Fujirebio Diagnostics, Inc., a consolidated subsidiary of Miraca Holdings, Inc. and an industry leader in cancer biomarker assays, announced today that Cigna has added ROMA® (Risk of Ovarian Malignancy Algorithm) to its national preferred coverage list. Cigna Corporation is a global health service company dedicated to improving the health, well-being, and peace of mind of the customers they serve. This decision to add ROMA further demonstrates Cigna’s focus to help reduce patient health costs and achieve optimal health outcomes.

The ACOG (American College of Obstetricians and Gynecologists) recommendations include ROMA as one of several risk assessment algorithms when referring patients with an adnexal mass. ROMA is a qualitative test that combines the quantitative results of HE4, CA 125 and menopausal status into a numerical score. It can be performed in any laboratory that also provides CA 125 testing services. Each ROMA result automatically includes the individual results of CA 125, HE4 and the ROMA score. ROMA is intended to aid in assessing whether premenopausal or postmenopausal women who present with an ovarian adnexal mass are at high or low likelihood of finding malignancy on surgery. CA 125 is within normal limits in 50% of women with stage 1 disease, is often falsely positive in benign conditions like endometriosis, and is not approved as a risk assessment tool for ovarian masses. ROMA helps to address some of these shortcomings.

“With over 21,000 women in the U.S. diagnosed per year with ovarian cancer, we are pleased to see the increase in the number of women who will now have access to ROMA,” says Monte Wiltse, CEO/President at Fujirebio Diagnostics, Inc. “Early and appropriate care by a gynecologic oncologist can help increase survival rates in women with ovarian cancer and decrease the number of complications.”

About Fujirebio Diagnostics, Inc.

Fujirebio Diagnostics, Inc., a subsidiary of Fujirebio Holdings, Inc., is the premier cancer diagnostics company and the industry leader in cancer biomarker assays. The company pioneered and introduced CA 125, the first FDA approved ovarian cancer biomarker, over 25 years ago and introduced HE4 and ROMA for ovarian cancer management in 2008 and 2011, respectively. Fujirebio Diagnostics specializes in the clinical development, manufacturing and commercialization of in vitro diagnostic products for the management of human disease states, with an emphasis in oncology. For more information about Fujirebio Diagnostics, please call +1 610-240-3800 or visit us at http://www.he4test.com.

About Fujirebio

Fujirebio is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products. Fujirebio has a strong and long-lasting tradition of collaborating with experts in the worldwide clinical community in the development of high-quality routine and truly novel biomarkers that cover a variety of disease states. Its IVD product lines span the range from specialized manual and automated testing to fully automated routine clinical laboratory testing solutions.

Fujirebio is a wholly-owned subsidiary of Miraca Holdings Inc. (listed on the Tokyo Stock Exchange – TYO: 4544) and employs more than 1,200 people in Asia, Europe and America.

Share article on social media or email:

VITA NOVAS POSTER

“We have combined elements of Tele-health with Regenerative therapy, IV wellness ,and a direct-to-consumer model intending to offer medical services at the patient’s’ place of residence, due to convenience and social distancing practices,” explains Benito Novas CEO Global Stem Cells Group

MIAMI (PRWEB)
May 21, 2020

Having the cushion of an already established worldwide network and 10 years of experience of GSCG, VITA NOVAS has already gained ground with the inherited reputation of quality, innovation, and professionalism. The VITA NOVAS’ program delivers micro-nutrients , vitamins and stimulating biological products intravenously, guaranteeing an effective way for the ingredients to become immediately available to the cells. This greatly decreases the time it takes for the medication or supplements to take effect. Patient-centered carved out packages The Shield, the Fighter, and the Lightening are delivered on-demand to homes, offices, or hotels administered by certified healthcare professionals.

Believing on the precept of Prevent-Protect-Thrive, VITA NOVAS aspires to set standards in the industry, and committed to ensure in-home, and personalized patient service; keeping them away from hospitals and emergencies. VITA NOVAS offers infusion packages, mixed with essential fluids, electrolytes, vitamins, and antioxidants as a powerful cocktail to stimulate the immune system and help bolster it to assist in fighting infections and diseases. In-line with the evolved life pattern of social distancing, the process of treatment at VITA NOVAS is as simple as:

Select Your Service Area

Schedule a video consultation with our local doctors to discuss your possible treatment plan

Receive the treatment at home

“We have combined elements of Tele-health with Regenerative therapy, IV wellness infusions, and a direct-to-consumer model intending to serve at the patient’s’ place of residence, due to convenience and social distancing practices,” explains Benito Novas , CEO of VITA NOVAS.

The secret behind the VITA NOVAS program is the provision of assistance and prime incentives to medical professionals. Once a physician joins the network, the company provides training and support that they will need in order to set-up run, and market their practices. They enjoy geography and specialization exclusively as well as a strong network of patients referrals, increased revenues, and conduct consultations from home.

Global Stem Cells Group, with golden track record and experience of a decade, is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products, and solutions. Founded in 2010 by Benito Novas, the company combines dedicated researchers, physicians, patient educators, and solution providers with the shared goal of meeting the growing worldwide need for leading-edge Regenerative Medicine treatments. Global Stem Cells Groups corporate mission is to make the promise of Regenerative medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art regenerative technology, while adhering to the highest medical standards.

VITA NOVAS can help, to find your service area, please visit: http://www.vitanovas.net

To know more about the company, visit http://www.stemcellsgroup.com

Share article on social media or email:

“Stay Safe!”
Eduardo Galvan, CEO of First Aid Global LLC delivers donated PPE to The Salvation Army in downtown Los Angeles
Visit https://www.firstaidglobal.com/social-distance-warrior to help.

Think about the safety of your loved ones and those Americans who have compromising health problems as you visit restaurants and other businesses that are now opening

TARZANA, Calif. (PRWEB)
May 21, 2020

In today’s news cycle we often hear things that only lead to confusion. Whether or not to wear masks; to touch or shake hands with others; to avoid restaurants, movie theaters, concerts, sporting events or schools; or to lock yourself away in your home and get comfortable with your Netflix, AppleTV+, YoutubeTV or Prime Video subscriptions. But as things begin to return to normal Americans will still feel the effects of continuing transmission and bad news during this current health crisis.

“The best advice we can give is for people to stay vigilant, especially when it comes to making yourself vulnerable to disease transmission,” says Todd West, co-owner of First Aid Global LLC in Tarzana, CA. His company, ‘First Aid Global‘ supplies Personal Protective Equipment and has been warning of supply shortages for years. “The best time to prepare is obviously before a particular disaster and not when everybody else is buying or hoarding and depleting supplies. We look forward to putting current times behind us so that we can all go back to normal production.”

“Stay safe our there,” West says. “Think about the safety of your loved ones and those Americans who have compromising health problems as you visit restaurants and other businesses that are now opening.”

Share article on social media or email: